DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division

The commercialization effort follows the acquisition of a laboratory business with a tumor repository spanning over 130 tumor types.

Rhea-AI Summary

DataMeds AI (MEDS) has implemented cost controls, primarily reducing corporate management positions, to focus workforce spending on commercializing ChemoFx.

The diagnostic test helps oncologists select chemotherapy regimens, initially for gynecologic cancers only. ChemoFx was recently included for the first time in a Humana Medicaid coverage policy for gynecologic cancers. The update follows DataMeds' September 11, 2026 acquisition of Helomics, including its Predictive Oncology division.

Predictive Oncology controls over 70,000 de-identified tumor samples across over 130 tumor types, including approximately 20,000 ovarian cancer samples. DataMeds intends to seek research collaborations using data from the samples and is preparing additional ChemoFx data analyses for peer review. Discussions have begun with healthcare organizations about adding ChemoFx to cancer testing programs where appropriate.

6 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointChemoFx gained its first inclusion in a Humana Medicaid coverage policy for gynecologic cancers.
• Moderate pointHelomics acquisition completed September 11, 2026, including its Predictive Oncology division.
• Minor pointCost controls, primarily corporate management reductions, focus workforce spending on ChemoFx commercialization.
• Minor pointChemoFx discussions have begun with healthcare organizations about inclusion in cancer testing programs where appropriate.
• Minor point. Forward-looking: it has not happened yet and may not happen.Research collaborations are planned using de-identified data generated from Predictive Oncology's tumor samples.
• Minor point. Forward-looking: it has not happened yet and may not happen.Additional ChemoFx data analyses are being prepared for peer review concerning clinical utility in other solid tumors.

Negative

• None.

Key Figures

Peak historical annual revenue: Exceeding $25 million Tumor sample repository: Over 70,000 de-identified samples Tumor types: Over 130 +1 more

Peak historical annual revenue

Exceeding $25 million

ChemoFx under prior ownership

Tumor sample repository

Over 70,000 de-identified samples

Predictive Oncology repository

Tumor types

Over 130

Types represented in the repository

Ovarian cancer samples

Approximately 20,000

Samples in the repository

Historical Context

1 past event · Latest: Oct 12

1 event

1. Oct 12

   Coverage policy

   24h Move

   +3.7%

   Humana Medicaid policy added ChemoFx coverage for gynecologic cancers, with plan limitations.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

clia, laboratory-developed test, cpt codes, multi-omic data, +1 more

5 terms

clia regulatory

"operates a CLIA-certified clinical laboratory"

CLIA stands for the Clinical Laboratory Improvement Amendments, a U.S. federal program that sets quality and safety standards for laboratories that test human samples. For investors, a CLIA certification is like a safety inspection or license for a lab — it signals that test results are produced under accepted quality controls, affects a lab’s ability to sell or bill certain tests, and therefore influences a company’s regulatory risk, market access, and credibility.

laboratory-developed test medical

"The ChemoFx Assay is a laboratory-developed test (LDT)"

A laboratory-developed test is a diagnostic test that a single clinical laboratory designs, builds and uses in its own facility rather than buying from an outside manufacturer; think of it as a custom recipe made and run in-house for diagnosing disease. Investors care because these tests can be quicker to bring to market and create a revenue stream for labs, but they also carry regulatory and quality-risk differences that can affect demand, reimbursement and legal exposure.

cpt codes medical

"ChemoFx is billed under CPT codes 81535 and 81536."

CPT codes are standardized five-digit codes used to describe medical procedures, tests and services for billing, insurance reimbursement and data tracking. Think of them like barcodes for healthcare services: they tell payers what was done and influence how much providers get paid. Investors watch CPT codes because changes in coding, coverage or reimbursement rates can materially affect a healthcare provider’s revenue, equipment manufacturers’ sales and overall adoption of new treatments.

multi-omic data technical

"with artificial intelligence and multi-omic data."

Data sets that combine measurements from two or more biological “-omics” layers—for example genomics (DNA), transcriptomics (RNA), proteomics (proteins), metabolomics (metabolites) or epigenomics—collected from the same samples or subjects so they can be analyzed together. These data are generated by different laboratory technologies (sequencing, mass spectrometry, arrays, etc.) and are integrated using computational methods to reveal links across molecular layers, such as pathways, biomarkers, or mechanisms. Different omics types have different units, noise levels and coverage, so multi-omic analyses require normalization and specialized statistical or machine‑learning approaches to combine and interpret the disparate data.

organoid technology medical

"leveraging the sample repository and the Company's proprietary organoid technology."

A laboratory platform that grows three-dimensional, miniaturized versions of human tissues or organs from stem cells or patient-derived cells; these 'organoids' self-organize under specific culture conditions and growth signals to reproduce key cell types, structures and some functions of the original organ. Organoid technology is used for studying disease biology, testing drugs and modeling patient-specific responses, but organoids are not full, transplantable organs — they are smaller, lack full blood vessels and immune components, and vary in maturity and reproducibility depending on the protocols used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAMPA, FL / ACCESS Newswire / October 13, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx^™ and smart contracts platform PharmacyChain^™, today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on commercializing ChemoFx^® as a diagnostic lab test to help oncologists inform their chemotherapy regimen selection, initially for gynecologic cancers only. ChemoFx has recently been included, for the first time, in a Humana Medicaid coverage policy for gynecologic cancers.

Today's announcement comes following the September 11, 2026, DataMEDS acquisition of Helomics Corporation, which included Helomics' Predictive Oncology Cancer Biomarker Super Intelligence (SI) division.

"The ChemoFx test has been commercially available in the United States since 1997, has two dedicated CPT codes (81535/81536) and has been optimized through continual automation improvements for high test volumes, with peak historical annual revenues previously exceeding $25 million under prior ownership," said Gerald E. Commissiong, Interim Co-CEO of DataMEDS. "Leveraging DataMEDS' management team's deep relationships in oncology, we are preparing to relaunch a marketing campaign for ChemoFx. A landmark 2015 peer-reviewed publication in PLOS reviewed evidence supporting the clinical utility and cost-effectiveness of using the ChemoFx Assay for chemotherapy regimen selection in epithelial ovarian cancer (EOC). Based on our review of data generated since that publication, we believe there is an opportunity to publish additional clinical utility data for the ChemoFx Assay in other solid tumors, and we are preparing these additional data analyses for peer-review."

Mr. Commissiong continued, "Predictive Oncology controls a repository of over 70,000 de-identified tumor samples linked to de-identified clinical data in over 130 tumor types, including approximately 20,000 ovarian cancer samples. The Company intends to seek research collaborations, including with super intelligence (artificial intelligence) frontier lab developers, using de-identified data generated from its tumor samples. These potential collaborations could enable the discovery of new therapeutic targets leveraging the sample repository and the Company's proprietary organoid technology. The Company has begun discussions with hospital systems, Health Maintenance Organizations (HMOs), Group Purchasing Organizations (GPOs) and specialty cancer treatment centers to add ChemoFx to their cancer testing programs where appropriate."

DataMEDS plans to develop an oncology support module within the Health Lives Here app, which is now available for download on Android and iOS devices. The app, which is part of the "Health Lives Here" campaign, will facilitate the consolidation of electronic health records data for patients and the integration of wearables data, while producing a streamlined health dashboard for tracking purposes and access to unique products.

Corexa Health's pharmacy and distribution divisions are licensed to dispense and distribute chemotherapeutic drugs, respectively. Patients and providers who utilize the ChemoFx Assay are able choose their own pharmacy The Company's nutraceutical partner Tollo Health manufactures medical foods and dietary supplements. Tollo intends to build targeted nutritional support programs for cancer patients in consultation with leading oncologists.

Tollo Health, LLC is a company led by Interim Co-CEO Gerald Commissiong. Historical revenue is not necessarily indicative of future results.

For more information, visit www.datamedsai.com or contact James Lambert, Vice President at Rubenstein Public Relations, at jlambert@rubensteinpr.com or at 212-805-3024.

About Helomics Corporation

Helomics Corporation, a wholly owned subsidiary of DataMeds AI, Inc. (NASDAQ:MEDS), operates a CLIA-certified clinical laboratory in Pittsburgh, Pennsylvania, focused on precision oncology. Its flagship ChemoFx^® Assay tests a patient's live tumor cells against a panel of chemotherapy agents to give oncologists patient-specific information to help inform treatment decisions in gynecologic cancers. ChemoFx is billed under CPT codes 81535 and 81536. Through Predictive Oncology, its Cancer Biomarker Super Intelligence (SI) division, Helomics combines a large annotated biobank of tumor samples, from over 130 tumor types, with artificial intelligence and multi-omic data. It uses these to help pharmaceutical and biotechnology partners predict tumor response and speed up oncology drug discovery and development. The ChemoFx Assay is a laboratory-developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit https://predictive-oncology.com/ .

About DataMeds AI, Inc. (DBA DataMeds SI)

DataMeds SI (NASDAQ:MEDS) is a healthcare company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its Health IT platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates the super intelligence platform EinsteinRx^™ and blockchain-enabled smart contracts platform PharmacyChain^™ into Tollo Health, LLC's Health Lives Here mobile application, and its Corexa Pharmacy provides pharmacy dispensing and related services, including the distribution of products developed by Tollo Health. The Company's Helomics Corporation subsidiary operates a CLIA-certified laboratory in Pittsburgh offering the ChemoFx^® Assay.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, statements regarding the Company's ability to obtain coverage and reimbursement from other payers, including Medicare and commercial plans; reimbursement rates and collections for CPT codes 81535 and 81536; demand for and adoption of the ChemoFx Assay; the Helomics laboratory's capacity, automation and compliance with CLIA and state requirements, and the regulatory status of laboratory-developed tests; the Company's plans to publish ChemoFx data and the results of any such analyses; the integration of Helomics following its acquisition; the Company's anticipated business strategy, operating plans and growth opportunities; the cost-control measures and workforce reductions and their expected effects; the relaunch of ChemoFx marketing and the outcome of discussions with hospital systems, HMOs, group purchasing organizations and cancer treatment centers; the continuation of Humana's Medicaid coverage policy; the Company's ability to establish research collaborations and to use its tumor sample repository and related data in compliance with patient consents and privacy laws; the development of the Company's organoid technology; the planned oncology module within the Health Lives Here application; Tollo Health's planned nutritional support programs; that historical revenue of the ChemoFx business may not be indicative of future results; the Company's ability to maintain compliance with Nasdaq listing standards, the development of a proprietary blockchain and the development of provider-network features, the creation of the Health Lives Here pharmacy network, the success of the NFL Alumni Health partnership, the companies' proposed transaction with DataVault AI Inc. (NASDAQ: DVLT), Scilex Holding Company, EOS Holdings and HealthBridge Advisors (controlling shareholder of Tollo Health, LLC); the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the companies' ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the companies' technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

DataMeds AI Media Contact

James Lambert, Vice President
Rubenstein Public Relations
Phone: 212.805.3024
Email: jlambert@rubensteinpr.com

DataMeds AI Investor Contact

Investor Relations: IR@datamedsai.com

SOURCE: DataMEDS AI, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What cost controls has DataMeds AI implemented for ChemoFx commercialization?

DataMeds has implemented cost controls primarily through reductions in corporate management positions. The company gives focusing workforce spending on ChemoFx commercialization, initially for gynecologic cancers only, as the reason.

What new insurance coverage policy includes DataMeds AI's ChemoFx test?

ChemoFx was recently included for the first time in a Humana Medicaid coverage policy for gynecologic cancers. The test helps oncologists inform their chemotherapy regimen selection.